Pinnacle Medicines, a biotechnology company pioneering the development of oral peptide therapeutics using proprietary AI and physics-based platforms, today announced the closing of an oversubscribed $89 million Series B financing. The round was co-led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA Capital Management, Logos Capital and existing investors including OrbiMed.

Pinnacle Medicines is a biotechnology company focused on developing a new generation of oral peptide therapeutics designed to deliver biologic-level efficacy with the convenience of oral dosing. The company is building a differentiated discovery platform that integrates physics-based molecular simulations, artificial intelligence - enabled design, and advanced peptide chemistry to rationally design and optimize peptide medicines. Pinnacle is advancing a pipeline of potential first- and best-in-class oral peptide programs targeting validated pathways in immunology and cardiometabolic diseases.